$MAZE News
Last published 3d ago
- 3d agoMAZEMaze Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 3d agoMAZEMaze Therapeutics Reports Third Quarter 2026 Financial Results and Recent HighlightsGlobeNewswireEnrollment completed in Phase 2 HORIZON trial of MZE829; data from all three cohorts expected in early 2027 Enrollment ongoing in Phase 2 CIPheR trial of MZE782 in PKU; topline data expected in 2027 Phase 2 trial of
- 3d agoMAZEMaze Therapeutics Reports Third Quarter 2026 Financial Results and Recent HighlightsGlobeNewswireEnrollment completed in Phase 2 HORIZON trial of MZE829; data from all three cohorts expected in early 2027
- 1w agoMAZEMaze Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney
- 1mo agoMAZEMaze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026GlobeNewswireOral presentation will highlight previously reported Phase 2 HORIZON data for MZE829 in patients with APOL1-mediated kidney disease Two poster presentations will highlight preclinical research supporting the
- 2mo agoMAZEWells Fargo 21st Annual Healthcare Conference - MAZE THERAPEUTICS INCEarnings Call TranscriptsAll right. Hi, everyone. Thanks for joining us at the Wells Fargo Healthcare Conference. My name is Sadia Rahman. I'm one of the biotech analysts here at Wells Farga. And it's my pleasure to introduce Mays Therapeutics f
- 2mo agoMAZEWELLS FARGO 21ST ANNUAL HEALTHCARE CONFERENCE - MAZE THERAPEUTICS INCEarnings Call TranscriptsAll right. Hi, everyone. Thanks for joining us at the Wells Fargo Healthcare Conference. My name is Sadia Rahman. I'm one of the biotech analysts here at Wells Farga. And it's my pleasure to introduce Mays Therapeutics f
- 2mo agoMAZEMaze Therapeutics to Participate in Three Upcoming Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney
- 3mo agoMAZEMaze Therapeutics Announces Appointments to Its Board of DirectorsGlobeNewswirePaula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., join Maze’s Board of Directors, adding to the Company’s deep bench of clinical and industry experience SOUTH SAN FRANCISCO, Calif., Aug. 13, 2026
- 3mo agoMAZEMaze Therapeutics Reports Second Quarter 2026 Financial Results and Recent HighlightsGlobeNewswireEnrollment in Phase 2 HORIZON trial of MZE829 on track; data from all cohorts expected in late 2026 or early 2027 Phase 2 CIPheR trial of MZE782 in PKU initiated and enrollment ongoing; topline data expected in 2027
- 5mo agoMAZEMaze Therapeutics to Participate in Two Upcoming Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and
- 6mo agoMAZEMaze Therapeutics Reports First Quarter 2026 Financial Results and Recent HighlightsGlobeNewswirePositive topline data from Phase 2 HORIZON trial of MZE829 in patients with broad AMKD provide proof-of-concept and support advancement into pivotal trial; additional HORIZON data expected in late 2026 or early 2027
- 6mo agoMAZEMaze Therapeutics Announces $150 Million Registered OfferingGlobeNewswireSOUTH SAN FRANCISCO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE) today announced the pricing of its underwritten registered offering of 5,540,000 shares of its common stock at a
- 7mo agoMAZEMaze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent HighlightsGlobeNewswirePositive topline data from Phase 2 HORIZON trial of MZE829 demonstrating first clinical proof-of-concept in patients with broad AMKD to support advancement into pivotal program; Maze to host conference call today at 8:00
- 7mo agoMAZEMaze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney DiseaseGlobeNewswire– At week 12, treatment with MZE829 resulted in a 35.6% mean uACR reduction in broad AMKD patients, 50% of the patients achieved a greater than 30% reduction in uACR, and treatment was well-tolerated – – The subgroup of
- 8mo agoMLYSPROKIRONREGN+5Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsightPR NewswireRecently published Chronic Kidney Disease Market Insights report includes a comprehensive understanding of current treatment practices, chronic...
- 8mo agoMAZEMaze Therapeutics to Participate in the TD Cowen 46th Annual Health Care ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney
- 9mo agoMAZEMaze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026GlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney
- 10mo agoMAZEMaze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney
- 1y agoMAZEMaze Therapeutics Reports Third Quarter 2025 Financial Results and Recent HighlightsGlobeNewswireFirst-in-human data from Phase 1 trial of MZE782 support best- and first-in-class potential; two Phase 2 proof-of-concept trials in phenylketonuria (PKU) and chronic kidney disease (CKD) expected to initiate in 2026
- 1y agoMAZEMaze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney WeekGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney
- 1y agoMAZEMaze Therapeutics to Participate in Four Upcoming Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney
- 1y agoMAZEMaze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of DirectorsGlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney
- 1y agoMAZEMaze Therapeutics, Inc. (MAZE) Discusses MZE782 Phase 1 Healthy Volunteer Results (Transcript)Earnings Call Transcripts
- 1y agoMAZEMaze Therapeutics, Inc. (MAZE) Discuses On MZE782 Phase 1 Healthy Volunteer Trial Results Call (Transcript)Earnings Call Transcripts
- 1y agoMAZEMaze Therapeutics Announces Oversubscribed $150.0 Million Private PlacementGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney
- 1y agoMAZEMaze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD)GlobeNewswirePhase 1 data in healthy volunteers exceed expectations and support best-in-class potential, enabling Phase 2 advancement for both intended indications of PKU and CKD Dose-dependent urinary amino acid excretion
- 1y agoMAZEMaze Therapeutics Appoints Misbah Tahir as Chief Financial OfficerGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney
- 1y agoMAZEMaze Therapeutics Reports Second Quarter 2025 Financial Results and Recent HighlightsGlobeNewswireMZE782 Phase 1 Trial in Healthy Volunteers to Provide Proof of Mechanism Data for Phenylketonuria (PKU) and Chronic Kidney Disease (CKD) Expected in Q3 2025 MZE829 Phase 2 HORIZON Trial Actively Enrolling Patients with
- 1y agoMAZEMaze Therapeutics to Participate in Two Upcoming Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal,
- 1y agoMAZEMaze Therapeutics to Participate in the Jefferies 2025 Global Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal,
- 1y agoMAZEMaze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming MilestonesGlobeNewswireMZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease; Initial Data Expected in Q1 2026 MZE782 Phase 1 Healthy Volunteer Trial Ongoing; Initial Data Expected in Q3 2025 Strong Balance Sheet with
- 1y agoMAZEMaze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal,
- 1y agoMAZEMaze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent HighlightsGlobeNewswireMZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease (AKD); Initial Data Expected in Q1 2026 MZE782 Phase 1 Healthy Volunteer Trial Ongoing; Initial Data Expected in H2 2025 Raised $140 Million in
- 1y agoMAZEMaze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney DiseaseGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule
- 1y agoMAZEMaze Therapeutics Announces Pricing of Upsized Initial Public OfferingGlobeNewswireSOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule